| Primary information |
|---|
| sequence ID | Seq_9645 |
| Peptide sequence | YADKPETTKEQLGEF |
| CancerPDF_ID | CancerPDF_ID147, CancerPDF_ID8234, CancerPDF_ID8235, CancerPDF_ID10297, CancerPDF_ID11076, CancerPDF_ID11077, CancerPDF_ID11096, CancerPDF_ID11097, |
| PMID | 17269714,24982608,24982608,21805675,26482227,26482227,26482227,26482227 |
| Protein Name | Alpha1-acid glycoprotein 1,Alpha-1-acid glycoprotein 1,Alpha-1-acid glycoprotein 2,Alpha-1-acid glycoprotein 1,A1AG1_HUMAN,A1AG2_HUMAN,A1AG1_HUMAN,A1AG2_HUMAN |
| UniprotKB Entry Name | A1AG1_HUMAN,A1AG1_HUMAN,A1AG2_HUMAN,A1AG1_HUMAN,A1AG1_HUMAN,A1AG2_HUMAN,A1AG1_HUMAN,A1AG2_HUMAN |
| Fluid | Plasma,Urine,Urine,Urine,Urine,Urine,Urine,Urine |
| M/Z | NA,NA,NA,1755.8646,1755.759,1755.759,1755.8,1755.8 |
| Charge | 1,NA,NA,NA,NA,NA,NA,NA |
| Mass (in Da) | 1755.84,NA,NA,NA,NA,NA,NA,NA |
| fdr | NA,NA,NA,NA,NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,Nano-LC-MS,Nano-LC-MS,MALDI-TOF,MALDI-TOF,MALDI-TOF,MALDI-TOF,MALDI-TOF |
| Peptide Identification technique | LC-MS/MS,MS/MS,MS/MS,MALDI-TOF-MS,LC-ESI-MS/MS,LC-ESI-MS/MS,LC-ESI-MS/MS,LC-ESI-MS/MS |
| Quantification Technique | NA,NA,NA,NA,NA,NA,NA,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,0.01,0.01,1,FDR less than 5 %,FDR less than 5 %,FDR less than 5 %,FDR less than 5 % |
| CancerPDF_ID | CancerPDF_ID147, CancerPDF_ID8234, CancerPDF_ID8235, CancerPDF_ID10297, CancerPDF_ID11076, CancerPDF_ID11077, CancerPDF_ID11096, CancerPDF_ID11097, |
| p-Value | NA,NA,NA,NA,NA,NA,less than 0.05,less than 0.05 |
| Software | MASCOT (v 2.1.0),"GPM search engine, MASCOT","GPM search engine, MASCOT",NA,MASCOT,MASCOT,MASCOT,MASCOT |
| Length | 15,15,15,15,NA,NA,NA,NA |
| Cancer Type | Normal,Ovarian cancer,Ovarian cancer,Muscle-invasive bladder cancer,Clear cell renal carcinoma,Clear cell renal carcinoma,Clear cell renal carcinoma,Clear cell renal carcinoma |
| Database | MSDB Human Database,IPI 3.71 Human Database ,IPI 3.71 Human Database ,SwissProt Database,SwissProt Database,SwissProt Database,SwissProt Database,SwissProt Database |
| Modification | NA,NA,NA,NA,NA,NA,NA,NA |
| Number of Patients | NA,6 Ovarian cancer patients and 6 normal individuals,6 Ovarian cancer patients and 6 normal individuals,751 bladder cancer and 127 control,"117 clear cell RCC patients (ccRCC) (72 men, 45 women)","117 clear cell RCC patients (ccRCC) (72 men, 45 women)","117 clear cell RCC patients (ccRCC) (72 men, 45 women)","117 clear cell RCC patients (ccRCC) (72 men, 45 women)" |
| Regulation | NA,Uniquely present in case of urine of ovarian cancer patients,Uniquely present in case of urine of ovarian cancer patients,Differentially expressed between cancer vs normal samples,"Upregulated with increse in tumor mass,primary tumor stage","Upregulated with increse in tumor mass,primary tumor stage",Downregulated in pT1b compared to pT1a patients,Downregulated in pT1b compared to pT1a patients |
| Validation | NA,NA,NA,Mann-Whitney tests and areas under receiver-operator characteristic,external cross validation not done,external cross validation not done,external cross validation not done,external cross validation not done |
| Sensitivity | NA,NA,NA,NA,NA,NA,NA,NA |
| Specificity | NA,NA,NA,NA,NA,NA,NA,NA |
| Accuracy | NA,NA,NA,NA,NA,NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | |